RBCC Retains New IR Group to Optimize Investor Outreach, Relay Key Growth Plans

  RBCC Retains New IR Group to Optimize Investor Outreach, Relay Key Growth

Business Wire

NOKOMIS, Fla. -- February 13, 2013

Rainbow Coral Corp. (OTCBB: RBCC) is kicking-off a new investor outreach
campaign by hiring an up-and-coming, dynamic investor relations group
committed to enhancing the visibility and reach of RBCC’s strategic growth

“Our new investor relations partners have the hands-on expertise and industry
relevance we need to thoroughly communicate our corporate plans and activities
to current and potential investors as timely and efficiently as possible,”
said RBCC CEO Patrick Brown. “We’re confident that 2013 is shaping up to be an
incredible year for RBCC, and we want to make sure that it doesn’t go

RBCC’s biotech division, Rainbow BioSciences, maintains high interest in the
Bio-Assembler, a biotech device owned by RBCC partner Nano3D BioSciences. This
new technology enables scientists to grow cells in a three-dimensional
environment using nanoparticles that produce magnetic fields to lift cells
from the bottom of petri dishes.

These 3D cultures form tissues that more closely resemble those found in the
human body, as compared to conventional cell cultures grown on flat surfaces.
This valuable technique has the potential to drastically reduce the cost of
developing new drugs as well as eliminate the use of animals when testing the
safety of manufactured chemicals. Additionally, the Bio-Assembler has the
profound potential to grow functional organs from scratch.

RBCC is closely working with Nano3D to further develop and market the
Bio-Assembler worldwide – and by retaining an adept investor relations group,
RBCC is laying the foundation for an efficiently executed and far-reaching
growth strategy.

For more information on Rainbow BioSciences, please

Rainbow BioSciences will develop new medical and research technology
innovations to compete alongside companies such as Bristol Myers Squibb Co.
(NYSE:BMY),Biogen Idec Inc. (NASDAQ:BIIB), Abbott Laboratories (NYSE:ABT)
and Amgen Inc. (NASDAQ:AMGN).

About Rainbow BioSciences

Rainbow BioSciences, LLC, is a wholly owned subsidiary of Rainbow Coral Corp.
(OTCBB:RBCC). The Company continually seeks out new partnerships with
biotechnology developers to deliver profitable new medical technologies and
innovations. For more information on our growth-oriented business initiatives,
please visit our website at [www.RainbowBioSciences.com]. For investment
information and performance data on the Company, please

Notice Regarding Forward-Looking Statements

Safe Harbor Statement under the Private Securities Litigation Reform Act of
1995: This news release contains forward-looking information within the
meaning of Section 27A of the Securities Act of 1933, as amended, and Section
21E of the Securities Exchange Act of 1934, as amended, including statements
that include the words "believes," "expects," "anticipate" or similar
expressions. Such forward-looking statements involve known and unknown risks,
uncertainties and other factors that may cause the actual results, performance
or achievements of the Company to differ materially from those expressed or
implied by such forward-looking statements. In addition, description of
anyone's past success, either financial or strategic, is no guarantee of
future success. This news release speaks as of the date first set forth above
and the Company assumes no responsibility to update the information included
herein for events occurring after the date hereof.


Rainbow Coral Corp.
Patrick Brown, 813-367-9511
President and CEO
Press spacebar to pause and continue. Press esc to stop.